Annovis Bio Inc. (ANVS) announces patients treated with ANVS401 for 25 days showed statistically significant cognitive improvement as measured by the Alzheimer’s Disease Scale
This is the first double-blind, placebo-controlled study that shows cognitive improvements in AD patients as measured by ADAS-Cog and functional improvements in PD patients as measured by the Unified Parkinson's Disease Rating Scale (UPDRS)
At first look . . . very positive report! The market likes the outcome of the study!! Great to hear good news!!
Anything which appears to show benefits to actual human beings and not just in fruit flies, worms, mice, rats, or monkeys is exciting to me. Thanks for sharing!
Double-blind, placebo-controlled studies are good!
it was double-blinded, but it was not really placebo-controlled. I was told that the dose I received might be 5, 10, 20, or 40 mg of Posiphen (Synonyms: ANVS-401, (+)-phenserine, Posiphen tartrate .) Maybe they consider a 5 mg dose as a placebo. alzforum.org/therapeutics/p...
Thanks for sharing. Did you feel any improvement?
mentally - yes, but my balance became worse. I don't know how much it is related to the medicine and I don't know what dose I consumed
Were PwP participants taking their usual PD meds at the same time? Thank you for sharing.
"my balance became worse"
I'm in a positive mode today and speculate that it might be a recovery symptom from the treatment. If the neural pathways are cleaned up, it might be that the signals to (and feedback from) the muscles become stronger. So it may take some time for the CNS to adapt . I would have focused on balance training for a period to see if improves.
how much of this news relates to PD? I saw the features as well and thought it only related to Alzheimers?
they believe that every patient is a type of unique mix of Alz and PD
Among the enrolled patients, half were pwp
"it was double-blinded, but it was not really placebo-controlled. I was told that the dose I received might be 5, 10, 20, or 40 mg of Posiphen"
Thanks for sharing. Always interesting to hear first hand info from a participant.
I wonder if it could be that you were not among the first 14 PD, but in the second group of 40 to investigate optimal dose?
"The first 14 PD plus 14 AD patients, whose data are reported here, have finished treatment and their biomarkers are being measured. Recently, Annovis Bio reported the results of the measurement of inflammation in the first 14 PD patients using four biomarkers. The last 40 patients are being treated with different doses to determine the optimal dose. The study compares, in both patient populations, how nerve cells die by measuring all the steps in the toxic cascade leading to nerve cell death and how ANVS401 reverses the toxic cascade and recovers normal brain and body function."
"This interim analysis includes data from the first 14 Parkinson’s patients who have completed treatment; nine were given ANVS401, and five received placebo."
Annovis Bio claims wins in Alzheimer's and Parkinson's, shares skyrocket; FDA delays decision for Omeros' narsoplimabendpts.com/annovis-bio-clai...
I would like to participate in the next trial, but very unlikely will be accepted, plus I had to travel to another town - 3 hours flight - three (3) times during one month 
Thanks, wish you best of luck. If I were in your place, I would prefer to join the next phase as well
Keep us updated, Stephen! Thank you for your service to the PD and AD communities!
It seems to me that if you participate in a trial you should be allowed to continue with the best guess of the proper dosage for as long as you like. That would provide multiple long term single participant open label trials to gather more info (and it just seems right).
Hello, were you able to continue with the next trial?
Seems like good news, lets hope the results that will be released in July/August of this year remain positive. Thanks for posting!
The naturally occurring molecule N-acetylcysteine (NAC) shows benefit in a clinical trial for Parkinson's Disease.
ANNOVIS BIO ANNOUNCES POSITIVE FDA FEEDBACK FOR BUNTANETAP PHASE 3 CLINICAL DEVELOPMENT IN PARKINSON'S DISEASE (ANVS401)
Too much Iron is link to Cardiovascular disease, diabetes, cancer, neurodegenerative diseaseMore science newsprepare for a dramatically worse progression of disease
